Haematological malignancies
Gene: SH2B3
PMID:37206266
2x families
- hom missense variant Val402Met:
functional performed on patient's fibroblasts demonstrated increased basal pSTAT5, pSTAT3 and increased pJAK2 + pSTAT5 after stimulation with IL-3, GH, GM-CSF and EPO
- hom fs Arg148Profs*40
functional performed in zebrafish demonstrated increased number of macrophages and thrombocytes
PMID:23908464;
1 fam with 2 affecteds with dev delay + autoimmunity + (1x) ALL, hom for Asp231Gly fs*3
PMID:38152053;
JMML cohort - 2x hom missense + 2x het PTCsCreated: 1 Feb 2024, 11:29 a.m. | Last Modified: 1 Feb 2024, 11:29 a.m.
Panel Version: 1.1502
Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal
Phenotypes
Myeloproliferation and multi-organ autoimmunity; juvenile myelomonocytic leukemia MONDO:001190, SH2B3-related
Publications
Variants in this GENE are reported as part of current diagnostic practice
Germline variants reported in association with increased risk for haematological malignancies.Created: 24 Jul 2020, 12:24 p.m. | Last Modified: 24 Jul 2020, 12:24 p.m.
Panel Version: 0.3496
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
Predisposition to haematological malignancies
Publications
Gene: sh2b3 has been classified as Amber List (Moderate Evidence).
Gene: sh2b3 has been classified as Green List (High Evidence).
Mode of inheritance for gene: SH2B3 was changed from BIALLELIC, autosomal or pseudoautosomal to BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Gene: sh2b3 has been classified as Green List (High Evidence).
Publications for gene: SH2B3 were set to 23908464; 27913496; 39316992; 27881370; 28484264
gene: SH2B3 was added gene: SH2B3 was added to Haematological malignancies cancer susceptibility. Sources: Curated sources,Expert Review Amber Mode of inheritance for gene: SH2B3 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: SH2B3 were set to 23908464; 27913496; 39316992; 27881370; 28484264 Phenotypes for gene: SH2B3 were set to Autoimmunity; No other known cancer risks; Class: familial predisp to leukaemia (typ AD); SH2B3-related familial ALL; ALL